111 related articles for article (PubMed ID: 25262798)
1. Virtual screening and discovery of novel aurora kinase inhibitors.
Raghu R; Devaraji V; Leena K; Riyaz SD; Rani PB; Kumar BS; Naik PK; Dubey PK; Velmurugan D; Vijayalakshmi M
Curr Top Med Chem; 2014; 14(17):2006-19. PubMed ID: 25262798
[TBL] [Abstract][Full Text] [Related]
2. Benzochalcones bearing pyrazoline moieties show anti-colorectal cancer activities and selective inhibitory effects on aurora kinases.
Shin SY; Yoon H; Hwang D; Ahn S; Kim DW; Koh D; Lee YH; Lim Y
Bioorg Med Chem; 2013 Nov; 21(22):7018-24. PubMed ID: 24095020
[TBL] [Abstract][Full Text] [Related]
3. The discovery of aurora kinase inhibitor by multi-docking-based virtual screening.
Kim JT; Jung SH; Kang SY; Ryu CK; Kang NS
Int J Mol Sci; 2014 Nov; 15(11):20403-12. PubMed ID: 25383681
[TBL] [Abstract][Full Text] [Related]
4. Identification of ligand efficient, fragment-like hits from an HTS library: structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo tautomers for Aurora kinase A selectivity.
Sarvagalla S; Singh VK; Ke YY; Shiao HY; Lin WH; Hsieh HP; Hsu JT; Coumar MS
J Comput Aided Mol Des; 2015 Jan; 29(1):89-100. PubMed ID: 25344840
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, in Vitro, and in Vivo Biological Evaluation and Molecular Docking Analysis of Novel 3-(3-oxo-substitutedphenyl-3-)4-(2-(piperidinyl)ethoxy)phenyl)propyl)-2H-chromen-2-one Derivatives as Anti-breast Cancer Agents.
Dube PN; Waghmare MN; Mokale SN
Chem Biol Drug Des; 2016 Apr; 87(4):608-17. PubMed ID: 26643017
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 2,4-disubstituted phthalazinones as Aurora kinase inhibitors.
Wang W; Feng X; Liu HX; Chen SW; Hui L
Bioorg Med Chem; 2018 Jul; 26(12):3217-3226. PubMed ID: 29705376
[TBL] [Abstract][Full Text] [Related]
7. Structure guided inhibitor designing of CDK2 and discovery of potential leads against cancer.
Kumar AV; Mohan K; Riyaz S
J Mol Model; 2013 Sep; 19(9):3581-9. PubMed ID: 23728955
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies.
Borisa AC; Bhatt HG
Eur J Med Chem; 2017 Nov; 140():1-19. PubMed ID: 28918096
[TBL] [Abstract][Full Text] [Related]
9. Aurora Kinase Inhibitors in Head and Neck Cancer.
Qi G; Liu J; Mi S; Tsunematsu T; Jin S; Shao W; Liu T; Ishimaru N; Tang B; Kudo Y
Curr Top Med Chem; 2018; 18(3):199-213. PubMed ID: 29332580
[TBL] [Abstract][Full Text] [Related]
10. Identification of Novel Aurora Kinase A (AURKA) Inhibitors via Hierarchical Ligand-Based Virtual Screening.
Kong Y; Bender A; Yan A
J Chem Inf Model; 2018 Jan; 58(1):36-47. PubMed ID: 29202231
[TBL] [Abstract][Full Text] [Related]
11. Theoretical Studies on Azaindoles as Human Aurora B Kinase Inhibitors: Docking, Pharmacophore and ADMET Studies.
Vadlakonda R; Nerella R; Enaganti S
Interdiscip Sci; 2018 Sep; 10(3):486-499. PubMed ID: 27981429
[TBL] [Abstract][Full Text] [Related]
12. Identification of 3,5,6-substituted indolin-2-one's inhibitors of Aurora B by development of a luminescent kinase assay.
Zhang L; Yang T; Xie X; Liu G
Bioorg Med Chem Lett; 2015 Aug; 25(15):2937-42. PubMed ID: 26048792
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and anticancer evaluation of novel spirobenzo[h]chromene and spirochromane derivatives with dual EGFR and B-RAF inhibitory activities.
Abdelatef SA; El-Saadi MT; Amin NH; Abdelazeem AH; Omar HA; Abdellatif KRA
Eur J Med Chem; 2018 Apr; 150():567-578. PubMed ID: 29549841
[TBL] [Abstract][Full Text] [Related]
14. Chromenylchalcones showing cytotoxicity on human colon cancer cell lines and in silico docking with aurora kinases.
Shin SY; Yoon H; Ahn S; Kim DW; Kim SH; Koh D; Lee YH; Lim Y
Bioorg Med Chem; 2013 Jul; 21(14):4250-8. PubMed ID: 23719279
[TBL] [Abstract][Full Text] [Related]
15. Leishmania donovani Aurora kinase: A promising therapeutic target against visceral leishmaniasis.
Chhajer R; Bhattacharyya A; Didwania N; Shadab M; Das N; Palit P; Vaidya T; Ali N
Biochim Biophys Acta; 2016 Sep; 1860(9):1973-88. PubMed ID: 27288586
[TBL] [Abstract][Full Text] [Related]
16. Ligand efficiency based approach for efficient virtual screening of compound libraries.
Ke YY; Coumar MS; Shiao HY; Wang WC; Chen CW; Song JS; Chen CH; Lin WH; Wu SH; Hsu JT; Chang CM; Hsieh HP
Eur J Med Chem; 2014 Aug; 83():226-35. PubMed ID: 24960626
[TBL] [Abstract][Full Text] [Related]
17. Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
Jagtap AD; Chang PT; Liu JR; Wang HC; Kondekar NB; Shen LJ; Tseng HW; Chen GS; Chern JW
Eur J Med Chem; 2014 Oct; 85():268-88. PubMed ID: 25089810
[TBL] [Abstract][Full Text] [Related]
18. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking.
Eldehna WM; Fares M; Ibrahim HS; Aly MH; Zada S; Ali MM; Abou-Seri SM; Abdel-Aziz HA; Abou El Ella DA
Eur J Med Chem; 2015 Jul; 100():89-97. PubMed ID: 26071861
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors.
Bruel A; Bénéteau R; Chabanne M; Lozach O; Le Guevel R; Ravache M; Bénédetti H; Meijer L; Logé C; Robert JM
Bioorg Med Chem Lett; 2014 Nov; 24(21):5037-40. PubMed ID: 25248682
[TBL] [Abstract][Full Text] [Related]
20. Substituted indolin-2-ones as p90 ribosomal S6 protein kinase 2 (RSK2) inhibitors: Molecular docking simulation and structure-activity relationship analysis.
Zhong Y; Xue M; Zhao X; Yuan J; Liu X; Huang J; Zhao Z; Li H; Xu Y
Bioorg Med Chem; 2013 Apr; 21(7):1724-34. PubMed ID: 23434140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
